New hope for multiple myeloma: cevostamab trial launches in china

NCT ID NCT06934044

Recruiting now Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 23, 2026 · Updated 23 times

Summary

This study tests a new drug called cevostamab in 20 Chinese patients whose multiple myeloma has come back or stopped responding to treatment. The goal is to see how the drug moves through the body, if it is safe, and if it helps shrink the cancer. Participants will receive the drug and be closely monitored for side effects and response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Sun yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China
The First Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, China
The First Affiliated Hospital of Wenzhou Medical University
RECRUITING

Wenzhou, 325035, China
Tianjin Institute of Hematology & Blood Diseases Hospital
RECRUITING

Tianjin, Tianjin Municipality, 301636, China
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
RECRUITING

Wuhan, 430030, China

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA